James Reasoner Apgar

This inventor holds 20 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Therapeutic Antibodies. Top assignees: Pfizer Corporation, Agrivida, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Reasoner Apgar. Retrieved from https://idiyas.com/inventor/james-reasoner-apgar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 13)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 5 (Patent Applications = 13)

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 49(Granted Patents)

Location History:

Somerville, MA (US) (2013 - 2020)
Newton, MA (US) (2019 - 2023)
Medford, MA (US) (2023)

Company Filing History:

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Anti-E-Selectin Antibodies

Anti-GDF15 Antibodies

Tissue Factor Pathway Inhibitor

Therapeutic Antibodies

Anti-IL-33 Antibodies

Intein-Modified Enzymes

Clotting Factor VIII

Cellulosic Processing Trait

Antagonist Antibodies

Compositions

Methods of Use

Industrial Applications

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577308 - ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE (2026-03-17),

2. 12227564 - Anti-GDF15 antibodies, compositions and methods of use (2025-02-18),

3. 12168698 - Tissue factor pathway inhibitor antibodies and uses thereof (2024-12-17),

4. 11840572 - Therapeutic antibodies and their uses (2023-12-12),

5. 11634504 - Tissue factor pathway inhibitor antibodies and uses thereof (2023-04-25),

6. 11597770 - Anti-E-selectin antibodies, compositions and methods of use (2023-03-07),

7. 11566066 - Anti-GDF15 antibodies, compositions and methods of use (2023-01-31),

8. 11434292 - Antibodies specific for CD3 and uses thereof (2022-09-06),

9. 10875929 - Tissue factor pathway inhibitor antibodies and uses thereof (2020-12-29),

10. 10570189 - Muteins of clotting factor VIII (2020-02-25),

11. 10550200 - Tissue factor pathway inhibitor antibodies and uses thereof (2020-02-04),

12. 10544212 - Anti-IL-33 antibodies, compositions, methods and uses thereof (2020-01-28),

13. 10407742 - Intein-modified enzymes, their production and industrial applications (2019-09-10),

14. 10196623 - Intein-modified enzymes, their production and industrial application (2019-02-05),

15. 9751937 - Antagonist antibodies against GDF-8 and uses therefor (2017-09-05),

Title: James Reasoner Apgar: A Trailblazer in Antibody Innovations

Introduction: James Reasoner Apgar, based in Newton, MA, is a prominent inventor with a remarkable portfolio of 19 patents. His work primarily focuses on the development of innovative antibody therapies that have extensive applications in medicine. Apgar's contributions to the scientific community are pivotal in advancing treatment options for various health conditions.

Latest Patents: Among his latest patents, Apgar has developed anti-GDF15 antibodies, which include compositions and methods of use. This invention provides antibodies that specifically bind to GDF15, along with their methods and applications. Another noteworthy patent is related to tissue factor pathway inhibitor (TFPI) antibodies, which are specifically designed to inhibit the activity of TFPI. These antibodies have significant potential in treating bleeding disorders and effectively shortening clotting times.

Career Highlights: Throughout his esteemed career, Apgar has made significant strides in the biotechnology field. He has worked with notable companies such as Pfizer Corporation and Agrivida, Inc., contributing to important developments in antibody therapies and their applications.

Collaborations: Apgar's journey has led him to collaborate with esteemed professionals in his field. Notable coworkers include Binzhang Shen and R. Michael Raab, with whom he has shared insights and research in the development of groundbreaking therapeutic solutions.

Conclusion: James Reasoner Apgar exemplifies the spirit of innovation and dedication in the biotechnology industry. Through his extensive work on antibodies and collaborations with reputed companies and professionals, he continues to influence the direction of medical treatments and contribute to the fight against various health challenges. His impressive patent portfolio underscores his commitment to driving advancements in biotechnology and improving patient outcomes.

Profile summary based on public USPTO records.